These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35354614)

  • 21. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
    Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
    Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
    J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
    Newsome PN; Buchholtz K; Cusi K; Linder M; Okanoue T; Ratziu V; Sanyal AJ; Sejling AS; Harrison SA;
    N Engl J Med; 2021 Mar; 384(12):1113-1124. PubMed ID: 33185364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.
    Friedman S; Sanyal A; Goodman Z; Lefebvre E; Gottwald M; Fischer L; Ratziu V
    Contemp Clin Trials; 2016 Mar; 47():356-65. PubMed ID: 26944023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis.
    Amin NB; Carvajal-Gonzalez S; Purkal J; Zhu T; Crowley C; Perez S; Chidsey K; Kim AM; Goodwin B
    Sci Transl Med; 2019 Nov; 11(520):. PubMed ID: 31776293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design.
    Anstee QM; Neuschwander-Tetri BA; Wong VW; Abdelmalek MF; Younossi ZM; Yuan J; Pecoraro ML; Seyedkazemi S; Fischer L; Bedossa P; Goodman Z; Alkhouri N; Tacke F; Sanyal A
    Contemp Clin Trials; 2020 Feb; 89():105922. PubMed ID: 31881392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
    Francque SM; Bedossa P; Ratziu V; Anstee QM; Bugianesi E; Sanyal AJ; Loomba R; Harrison SA; Balabanska R; Mateva L; Lanthier N; Alkhouri N; Moreno C; Schattenberg JM; Stefanova-Petrova D; Vonghia L; Rouzier R; Guillaume M; Hodge A; Romero-Gómez M; Huot-Marchand P; Baudin M; Richard MP; Abitbol JL; Broqua P; Junien JL; Abdelmalek MF;
    N Engl J Med; 2021 Oct; 385(17):1547-1558. PubMed ID: 34670042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
    Bril F; Barb D; Lomonaco R; Lai J; Cusi K
    J Hepatol; 2020 Mar; 72(3):401-410. PubMed ID: 31589891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.
    Lawitz EJ; Coste A; Poordad F; Alkhouri N; Loo N; McColgan BJ; Tarrant JM; Nguyen T; Han L; Chung C; Ray AS; McHutchison JG; Subramanian GM; Myers RP; Middleton MS; Sirlin C; Loomba R; Nyangau E; Fitch M; Li K; Hellerstein M
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1983-1991.e3. PubMed ID: 29705265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.
    Ratziu V; Rinella ME; Neuschwander-Tetri BA; Lawitz E; Denham D; Kayali Z; Sheikh A; Kowdley KV; Desta T; Elkhashab M; DeGrauw J; Goodwin B; Ahmad A; Adda N
    J Hepatol; 2022 Mar; 76(3):506-517. PubMed ID: 34740705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
    Harrison SA; Thang C; Bolze S; Dewitt S; Hallakou-Bozec S; Dubourg J; Bedossa P; Cusi K; Ratziu V; Grouin JM; Moller DE; Fouqueray P
    J Hepatol; 2023 May; 78(5):914-925. PubMed ID: 36804402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
    Pedrosa M; Seyedkazemi S; Francque S; Sanyal A; Rinella M; Charlton M; Loomba R; Ratziu V; Kochuparampil J; Fischer L; Vaidyanathan S; Anstee QM
    Contemp Clin Trials; 2020 Jan; 88():105889. PubMed ID: 31731005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of acetyl-CoA carboxylase (ACC) inhibitors in the treatment of nonalcoholic steatohepatitis (NASH): A protocol for systematic review.
    Xu L; Yang H; Xu H; Yang R; Fen L; Jiang D; Xu L; Xing Y
    Medicine (Baltimore); 2022 Dec; 101(50):e32357. PubMed ID: 36550852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design.
    Zang S; Chen J; Song Y; Bai L; Chen J; Chi X; He F; Sheng H; Wang J; Xie S; Xie W; Yang Y; Zhang J; Zheng M; Zou Z; Wang B; Shi J;
    Adv Ther; 2018 Feb; 35(2):218-231. PubMed ID: 29411270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH.
    Ratziu V; Harrison SA; Loustaud-Ratti V; Bureau C; Lawitz E; Abdelmalek M; Alkhouri N; Francque S; Girma H; Darteil R; Couchoux H; Wolf M; Sanyal A; Vonderscher J; Scalfaro P
    J Hepatol; 2023 Mar; 78(3):479-492. PubMed ID: 36334688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis.
    Harrison SA; Marri SR; Chalasani N; Kohli R; Aronstein W; Thompson GA; Irish W; Miles MV; Xanthakos SA; Lawitz E; Noureddin M; Schiano TD; Siddiqui M; Sanyal A; Neuschwander-Tetri BA; Traber PG
    Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1183-1198. PubMed ID: 27778367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study.
    Iwaki M; Kessoku T; Tanaka K; Ozaki A; Kasai Y; Yamamoto A; Takahashi K; Kobayashi T; Nogami A; Honda Y; Ogawa Y; Imajo K; Yoneda M; Kobayashi N; Saito S; Nakajima A
    BMJ Open; 2022 Jul; 12(7):e060335. PubMed ID: 35820743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The rationale and study design of two phase II trials examining the effects of BI 685,509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis.
    Reiberger T; Berzigotti A; Trebicka J; Ertle J; Gashaw I; Swallow R; Tomisser A
    Trials; 2023 Apr; 24(1):293. PubMed ID: 37095557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems.
    Ross TT; Crowley C; Kelly KL; Rinaldi A; Beebe DA; Lech MP; Martinez RV; Carvajal-Gonzalez S; Boucher M; Hirenallur-Shanthappa D; Morin J; Opsahl AC; Vargas SR; Bence KK; Pfefferkorn JA; Esler WP
    Cell Mol Gastroenterol Hepatol; 2020; 10(4):829-851. PubMed ID: 32526482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Sanyal A; Charles ED; Neuschwander-Tetri BA; Loomba R; Harrison SA; Abdelmalek MF; Lawitz EJ; Halegoua-DeMarzio D; Kundu S; Noviello S; Luo Y; Christian R
    Lancet; 2019 Dec; 392(10165):2705-2717. PubMed ID: 30554783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.